Prostate Hypoxia FAZA

University Health Network, Toronto

Status

Enrolling

Conditions

Prostate Cancer

Treatments

Other: 18F-Fluoroazomycin Arabinoside (18F-FAZA)

Study type

Interventional

Funder types

Other

Identifiers

NCT01567800

UHN REB 11-0953-C

Details and patient eligibility

About

The purpose of this study is to look for low levels of oxygen (hypoxia) in prostate cancer using a special x-ray test called a positron emission tomography (PET)scan. Hypoxia may have an effect on how prostate cancer grows and responds to treatments like radiotherapy and chemotherapy. The use of PET scans to measure hypoxia may be better and simpler than the methods used previously.

Enrollment

20 estimated patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age => 18 years
Histologic diagnosis of adenocarcinoma of the prostate
Bulky intermediate risk, high risk or metastatic prostate cancer

Bulky intermediate risk: cT1-2 with >50% of diagnostic biopsy cores containing cancer and Gleason 6 or 7 and prostate specific antigen (PSA) >10 and ≤20 OR

High risk:

cT1-2 with Gleason score ≥8; or cT1-2 with PSA >20; or cT3 OR N+ and/or M1 disease OR Newly diagnosed hormone-refractory prostate cancer - Intention to treat using radiotherapy +/- concurrent and adjuvant hormonal therapy

Intention to treat with radiotherapy, hormonal therapy, other systemic treatment for prostate cancer, or a combination of these according to the Princess Margaret Genitourinary Site policies.
Previous or concurrent anti-cancer therapy for the PET FAZA target lesion allowed
Ability to provide written informed consent to participate in the study

Exclusion criteria

Inability to lie supine for more than 60 minutes
Patients taking the drug disulfiram (Antabuse)
Contraindications for MRI: only applicable in cases where the PET FAZA target lesion is identified as the prostate gland. Patients with target lesions at other anatomic sites will not undergo MR imaging.
Patients weighing > 136 kg